Table 1

Demographic data and clinical characteristics—by cluster

CharacteristicCluster 1Cluster 2Cluster 3Cluster 4
Abatacept (n=35)Placebo (n=21)Total (n=56)Abatacept (n=11)Placebo (n=4)Total (n=15)Abatacept (n=22)Placebo (n=7)Total (n=29)Abatacept (n=27)Placebo (n=12)Total (n=39)
Age, years, mean (SD)41.9 (14.3)43.2 (11.3)42.4 (13.2)36.5 (12.8)37.5 (10.0)36.7 (11.8)35.0 (12.7)28.7 (8.9)33.5 (12.0)38.0 (9.0)34.3 (11.7)36.9 (9.9)
Female, n (%)31 (88.6)20 (95.2)51 (91.1)8 (72.7)4 (100.0)12 (80.0)17 (77.3)7 (100.0)24 (82.8)27 (100.0)11 (91.7)38 (97.4)
Race, n (%)
White29 (82.9)19 (90.5)48 (85.7)8 (72.7)3 (75.0)11 (73.3)12 (54.6)4 (57.1)16 (55.2)14 (51.9)7 (58.3)21 (53.9)
Black/African American1 (2.9)1 (4.8)2 (3.6)1 (9.1)0 (0.0)1 (6.7)4 (18.2)1 (14.3)5 (17.2)2 (7.4)2 (16.7)4 (10.3)
American Indian/Alaskan native0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (3.7)0 (0.0)1 (2.6)
Asian5 (14.3)1 (4.8)6 (10.7)2 (18.2)1 (25.0)3 (20.0)6 (27.3)2 (28.6)8 (27.6)7 (25.9)2 (16.7)9 (23.1)
Other0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (3.7)1 (8.3)2 (5.1)
Primary flare manifestation at screening, n (%)
Cutaneous–discoid lesions9 (25.7)3 (14.3)12 (21.4)6 (54.5)1 (25.0)7 (46.7)8 (36.4)1 (14.3)9 (31.0)10 (37.0)8 (66.7)18 (46.2)
Polyarthritis21 (60.0)13 (61.9)34 (60.7)4 (36.4)3 (75.0)7 (46.7)13 (59.1)5 (71.4)18 (62.1)13 (48.1)4 (33.3)17 (43.6)
Serositis (pleuritis/ pericarditis)5 (14.3)5 (23.8)10 (17.9)1 (9.1)0 (0.0)1 (6.7)1 (4.5)1 (14.3)2 (6.9)4 (14.8)0 (0.0)4 (10.3)
Concomitant steroid use, n (%)32 (91.4)16 (76.2)48 (85.7)7 (63.6)4 (100.0)11 (73.3)18 (81.8)6 (85.7)24 (82.8)21 (77.8)9 (75.0)30 (76.9)
Oral prednisone (or equivalent) dose, mg/day, mean (SD)28.6 (4.6)30.0 (0.0)ND30.0 (0.0)23.8 (12.5)ND28.9 (4.7)30.0 (0.0)ND29.0 (4.4)30.0 (0.0)ND
  • ND, not done.